Nexera Energy is finalizing its audited financials to lift a cease trade order and has secured partial revocation to raise $320,000 through a private placement. The company is restructuring its balance sheet by converting debt into equity, aiming to improve financial health. Nexera plans to transition from oil and gas to waste tire recycling using pyrolysis technology, pending regulatory approval, positioning itself for new growth opportunities.
Nexera Energy's recent regulatory and financial restructuring efforts provide context for market watchers. For readers following the energy sector, here is Pluang's market snapshot as of Sep 15, 2026 19:16 WIB: 21 of 30 priced US energy stocks rose today. Notable prices include Constellation Energy Corporation at USD 265.50, Canadian Natural Resources Ltd. at USD 50.15, and Occidental Petroleum Corporation at USD 61.98.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
